Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | -124.24% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.74 | N/A | -124.24% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance due to ongoing uncertainties. They emphasized their commitment to clinical development.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their clinical programs despite the current challenges.
Revolution Medicines reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, gaining 4.51%, likely due to optimism about their ongoing clinical programs. The lack of revenue data and guidance may leave investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENERGY TRANSFER L P
May 11, 2020